Active Ingredient History
2S,4R ketoconazole or levoketoconazole is the 2S,4R enantiomer of ketoconazole, purified from racemic ketoconazole. Both enantiomers exerts antifungal activity. Ketoconazole activates AhR in gene reporter cell line and dose-dependently induces CYP1A1 mRNA and CYP1A1 protein in HepG2 cells, with enantiospecific pattern, i.e. 2R,4S ketoconazole was much more active as compared to 2S,4R ketoconazole. Levoketoconazole was shown to be a more potent inhibitor than the 2R,4S enantiomer of several enzymes in the steroidogenic pathway (CYP11B1, CYP17 and CYP21). Levoketoconazole was tested for the treatment of endogenous Cushing’s syndrome (Phase III) and type 2 diabetes mellitus (Phase II). NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Blastomycosis (approved 1981)
Coccidioidomycosis (approved 1981)
Tinea (approved 1981)
Tinea Pedis (approved 1981)
Acne Vulgaris (Phase 3)
Acute Pain (Phase 2/Phase 3)
Agammaglobulinemia (Phase 1)
Alzheimer Disease (Phase 1)
Antimetabolites (Phase 1)
Asthma (Phase 1)
Astrocytoma (Early Phase 1)
Autoimmune Diseases (Phase 1)
Bacterial Infections (Phase 1)
Biological Availability (Phase 1)
Brain Neoplasms (Early Phase 1)
Breast Neoplasms (Phase 2)
Burns (Phase 2/Phase 3)
Candidiasis (Phase 3)
Candidiasis, Vulvovaginal (Phase 3)
Carcinoma (Phase 1)
Central Serous Chorioretinopathy (Phase 2)
Cushing Syndrome (Phase 3)
Deficiency Diseases (Phase 2)
Dermatitis, Seborrheic (Phase 4)
Dermatology (Phase 3)
Diabetes Mellitus, Type 2 (Phase 2/Phase 3)
Drug Interactions (Phase 1)
Drugs, Investigational (Phase 1)
Erectile Dysfunction (Phase 1)
Essential Hypertension (Phase 1)
Femur Head Necrosis (Phase 2)
Gastroparesis (Phase 1)
Glioblastoma (Early Phase 1)
Glioma (Early Phase 1)
Hair Follicle (Phase 4)
Hamartoma (Phase 1/Phase 2)
Healthy Volunteers (Phase 1/Phase 2)
Hematologic Neoplasms (Phase 1)
Hepatitis C (Phase 1)
Hip Fractures (Phase 2)
Hodgkin Disease (Phase 1)
Hormones (Phase 2)
Huntington Disease (Phase 1)
Hypogonadism (Phase 1)
Infant, Premature (Phase 1)
Insulin Resistance (Early Phase 1)
Kidney Transplantation (Phase 4)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia, Myeloid, Chronic-Phase (Phase 2)
Lung Diseases (Phase 3)
Lymphoma (Phase 1)
Lymphoma, Large-Cell, Anaplastic (Phase 1)
Lymphoma, Non-Hodgkin (Phase 1)
Macular Degeneration (Phase 1)
Melanoma (Phase 1)
Multiple Sclerosis (Phase 1)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 2)
Neuroblastoma (Phase 1)
Oligodendroglioma (Early Phase 1)
Onychomycosis (Phase 1)
Osteoarthritis (Phase 2)
Osteoporosis (Phase 1)
Ovarian Neoplasms (Phase 2)
Pharmacokinetics (Phase 1)
Pharmacology, Clinical (Phase 1)
Pituitary ACTH Hypersecretion (Phase 3)
Prostate (Phase 2)
Prostatic Neoplasms (Phase 3)
Psoriasis (Phase 2)
Pulmonary Disease, Chronic Obstructive (Phase 4)
Respiratory Distress Syndrome (Phase 3)
Schizophrenia (Phase 1)
Sleep Disorders, Intrinsic (Phase 1)
Thromboembolism (Phase 2)
Tinea (Phase 3)
Tinea Pedis (Phase 3)
Tinea Versicolor (Phase 4)
Vaginosis, Bacterial (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
